by | Jun 13, 2024 | Publications
Blood. 2024 Jun 13;143(24):2559. doi: 10.1182/blood.2024024221. NO ABSTRACT PMID:38869920 | DOI:10.1182/blood.2024024221
by | Jun 13, 2024 | Publications
Haematologica. 2024 Jun 13. doi: 10.3324/haematol.2024.285368. Online ahead of print. ABSTRACT Not available. PMID:38867588 | DOI:10.3324/haematol.2024.285368
by | Jun 13, 2024 | Publications
Clin Lab. 2024 Jun 1;70(6). doi: 10.7754/Clin.Lab.2024.231224. ABSTRACT BACKGROUND: Both humoral and cell-mediated immunity of the patient affected by multiple myeloma (MM) are impaired; thus, infection is the main cause of the onset of symptoms and death caused by...
by | Jun 13, 2024 | Publications
Oncogene. 2024 Jun 12. doi: 10.1038/s41388-024-03082-5. Online ahead of print. NO ABSTRACT PMID:38867079 | DOI:10.1038/s41388-024-03082-5
by | Jun 12, 2024 | Publications
Blood Adv. 2024 Jun 12:bloodadvances.2023010856. doi: 10.1182/bloodadvances.2023010856. Online ahead of print. ABSTRACT The identification and targeting of B cell maturation antigen (BCMA) through immunotherapeutic strategies such as antibody-drug conjugates (ADC),...
by | Jun 12, 2024 | Publications
Cancer Med. 2024 Jun;13(11):e7387. doi: 10.1002/cam4.7387. ABSTRACT BACKGROUND: Promising outcomes have been observed in multiple myeloma (MM) with the use of immunotherapies, specifically chimeric antigen receptor T (CAR-T) cell therapy. However, a portion of MM...
